v3.26.3
Commitments and Contingencies
3 Months Ended
Sep. 30, 2026
Commitments and Contingencies  
Commitments and Contingencies

Note 10 - Commitments and Contingencies

Legal Proceedings

From time to time, we are subject to various legal proceedings arising in the ordinary course of business, including proceedings for which we have insurance coverage. There are no pending legal proceedings against the Company to the best of the Company’s knowledge as of the date hereof and to the Company’s knowledge no action, suit or proceeding has been threatened against the Company that we believe will have a material adverse effect to our business, financial position, results of operations, or liquidity.

Employment Agreements

As of July 1, 2026, NanoViricides, Inc. entered into an Extension Agreement (the “Extension”) of the 2025 Employment Agreement with Dr. Anil Diwan entered into on July 1, 2018 (the “Employment Agreement”) to continue to serve as the President and Executive Chairman of the Company, effective July 1, 2026 under the same general terms and conditions. The Extension provides that Dr. Diwan will continue to serve as the Company’s President until June 30, 2027 at an annual base salary of $400,000. Dr. Diwan shall be entitled to participate in all fringe benefits the Company provides for its employees generally and such other benefits as the Company provides for its senior executives. In addition, the Company shall maintain a Term Life Insurance policy for Dr. Diwan, valued at $2 million, of which $1 million shall be assigned to the Company and the remaining balance to Dr. Diwan’s estate. In addition, as an incentive towards the ultimate success of the Company, and to provide leadership authority to Dr. Diwan, the Company granted 10,204 shares of the Company’s Series A preferred stock, par value $0.00001 per share to Dr. Diwan. Dr. Diwan’s rights in the shares shall vest in equal, quarterly installments commencing on September 30, 2026 and fully vest on June 30, 2027. The Company will recognize non-cash compensation expense related to the issuance of the Series A preferred stock during the year ended June 30, 2027. Dr. Diwan will be eligible to receive severance if he is terminated by the Company other than for cause in which event the Company shall pay to Dr. Diwan an amount equal to six (6) month’s salary as severance compensation (without regard to compensation or benefits Dr. Diwan receives from any other source). Dr. Diwan shall be eligible for all benefits during this six (6) month period including bonuses, vesting of previously awarded stock options, health care insurance and other fringe benefits that have been ongoing. The Company may elect to pay such severance compensation in a lump sum or in equal payments over the six month period.

On March 3, 2010, the Company entered into an employment agreement with Dr. Jayant Tatake to serve as Vice President of Research and Development. The employment agreement provides for a term of four years with a base salary of $150,000. In addition, the Company issued 1,340 shares of Series A preferred stock and 1,786 shares of common stock upon entering into the agreement, and will issue an additional 1,340 shares of Series A preferred stock and 1,786 shares of common stock on each anniversary date of the agreement. The shares of Series A preferred stock were issued in recognition of Dr. Tatake’s work towards the achievement of several patents by the Company. The Compensation Committee of the Board of Directors has extended the current provisions of the employment agreement pending its review of current industry compensation arrangements and employment agreements.

As of July 1, 2026, NanoViricides, Inc. consummated an Extension to the CFO Agreement with its Chief Financial Officer Meeta Vyas effective July 1, 2026 (the “CFO Agreement Extension”) of the agreement originally entered into on May 30, 2013. The agreement is renewable on an annual basis. The original agreement provided for a term of three years with a base compensation of $9,000 per month and 129 shares of Series A Preferred Stock, also on a monthly basis. On January 1, 2015, her cash compensation was increased to $10,800 per month. The CFO Agreement Extension is for a period of one year from July 1, 2026 through June 30, 2027 under the same general terms as the prior CFO Agreement.

License Agreements

The Company is dependent upon its license agreements with TheraCour (See Notes 4). If the Company lost the right to utilize any of the proprietary information that is the subject of the TheraCour license agreement on which it depends, the Company will incur substantial delays and costs in development of its drug candidates. On November 1, 2019, the Company entered into a VZV License Agreement with TheraCour for an exclusive license for the Company to use, promote, offer for sale, import, export, sell and distribute products for the treatment of VZV derived indications. Process development and related work will be performed by TheraCour under the same compensation terms as prior agreements between the parties, with no duplication of costs allowed.

On September 7, 2021, the Company entered into a COVID-19 License Agreement to use, promote, offer for sale, import, export, sell and distribute drugs that treat COVID-19 infections, using TheraCour’s proprietary as well as patented technology and intellectual property. The discovery of ligands and polymer materials as well as formulations, the chemistry and chemical characterization, as well as process development and related work will be performed by TheraCour under the same compensation terms as prior agreements between the parties, with no duplication of costs allowed.

On March 27, 2023 the Company entered into a license agreement with KMPL wherein the Company granted to KMPL a limited, non-transferable, exclusive license for the use, sale, or offer of sale in India of the Company’s two clinical test drug candidates titled as NV-CoV-2 and NV-CoV-2-R for the treatment of COVID in patients in India. KMPL has engaged in further drug development in India including sponsoring of drug candidates for human clinical trials in India and has acted as clinical trials manager for such clinical trials. KMPL shall provide NanoViricides with all reports of the clinical trials and the Company can use such reports for further advancement of the drug candidates with regulatory authorities outside India. In consideration, KMPL will receive a customary clinical trials manager fee of thirty percent (30%) of such costs and applicable taxes. Upon commercialization, the Company will receive from KMPL a royalty of 70% calculated as the percentage of final invoiced sales less the cost of sales and goods sold to unaffiliated third parties.

On February 12, 2024, the Company entered into an Amendment to the COVID License Agreement with TheraCour dated September 7, 2021, whereby any further cash milestone payments that would be earned upon milestone event would only become payable upon the Company having sufficient revenues, with only a portion of revenues to be used for satisfying such milestone payments.

On September 23, 2024 and effective as of September 20, 2024, the Company entered into a “Memorandum of Understanding for All Antivirals Drug Development” (the MoU) with TheraCour that granted to the Company, a limited, non-assignable, non-sublicensable, exclusive Right of First Refusal to License to any antiviral drugs in development or to be developed by TheraCour for research and development purposes only, for all as-yet unlicensed viral infection treatment indications. The MoU also clarified the roles and responsibilities of the Parties and essentially codified the process that the parties have adopted since inception. The MoU further codified the treatment of all future milestone payments arising from any current or future license agreements to TheraCour to be consistent with the principles adopted in the February 12, 2024 Amendment to the COVID-19 License Agreement.

Clinical Trial Agreements

On June 20, 2024, we had entered into a Master Services Agreement (KMPL-MSA) with KMPL. This MSA enabled starting new projects in a specified manner without having to go through a complete agreement process.

In August, 2024, in the context of initiating a Phase II Clinical Trial for evaluating NV-387 as a Treatment for Mpox infections in the African Region, KMPL introduced the Company to Om Sai Clinical Research Private Limited, of Sangli, Maharashtra, India (“Om Sai”), a CRO with long-standing clinical trial site relationships in the African region where an MPox pandemic had broken out and was declared a Public Health Emergency of International Concern (“PHEIC”) by the WHO on August 16, 2024. The Mpox epidemic is still in progress DRC, although the case loads have decreased substantially.

In October 2024, we authorized KMPL to serve as Project Manager for our Phase II clinical trial of Mpox in DRC under the KMPL-MSA. KMPL brought in Om Sai Clinical Research Pvt. Ltd., India, to serve as CRO for this clinical trial. According to this agreement, we will pay KMPL project management fees of up to 30% over the cost of the clinical trial.

On October 10, 2024 a Phase II Clinical Trial Contract for the MPox Clinical Trial evaluating NV-387, was entered into between Om Sai Clinical Research Private Limited, as the CRO, and the Company. Om Sai is an independent third party and is not a related party.

The Company has incurred approximately $1,632,000 towards the Mpox clinical trial, of which approximately $794,000 has been paid, and approximately $838,000 has not been paid. The unpaid balance consisted of approximately $226,000 of clinical trial expenses, and approximately $306,000 for clinical trial management fees payable to KMPL, both which have both been reported as Accrued Expenses-related party, and approximately $306,000 for clinical trial CRO fees payable to Om Sai which has been reported as Accrued Expenses. The Company estimates that the total additional cost to complete Phase II clinical trial for evaluating NV-387 Oral Gummies as a Treatment for Mpox that remains payable to the Clinical Trial execution teams, and regulatory affairs, will be approximately $734,000.

On May 16, 2026, a new outbreak of a novel strain of the Ebola Bundibugyo virus was found to have started leading the WHO to declare a PHEIC for Ebola. The Company determined that NV-387 had a significant likelihood of being able to make a difference in this Ebola epidemic, since it was demonstrated to be a broad-spectrum antiviral agent in several animal studies, and because NV-387 is only anti-Ebola drug candidate that can be administered orally.

On or about May 24, 2026, the Company engaged KMPL as the Clinical Trial Project Manager, and Om Sai as the CRO to lead the clinical trial, for Phase II Ebola Project. This, the Company’s second Phase II clinical trial. This Phase II Clinical Trial is for evaluating NV-387 Oral Gummies for the treatment of indications of the Bundibugyo Ebola virus and other Ebola viruses. The Company negotiated with KMPL that we will pay KMPL project management fees of up to 20% over the cost of the clinical trial for the Ebola clinical trial. The Ebola clinical trial execution costs are substantially greater than those for the Mpox clinical trial. Therefore, KMPL agreed to the reduced management fee.

The Mpox and Ebola Phase II Clinical Trial Projects, as well as retaining KMPL as project managers for both trials, and retaining Om Sai as CRO for both trials have been approved by the Board of directors as we progressed in the various activities.

In June 2026, the Company was informed by the specially constituted Pillar Committee for Ebola Response in DRC that its proposal for the Phase II clinical trial of NV-387 Oral Gummies as a Treatment for Ebola was accepted for consideration and that the Company may proceed to obtain first, an Ethics Committee approval and then, the ACOREP local regulatory body approval for initiating the clinical trial. On or about July 4, 2026, the Company received Ethics Committee approval.

On or about July 7, 2026 the Company made an advance payment to initiate certain procedures that were required prior to filing the application for regulatory approval of the clinical trial. Subsequently, on July 10, 2026, the application was submitted to ACOREP, and on or about August 4, 2026, the Company received regulatory approval to conduct the clinical trial from ACOREP. The regulatory approval satisfied the conditions perfecting the Company’s financial commitment for the clinical trial.

The Company had incurred expenses of approximately $2,712,000 towards the Ebola clinical trial, of which as of September 30, 2026 approximately $1,658,000 had been paid. The unpaid balance of approximately $1,054,000 consisting of approximately $279,000 of clinical trial expenses, and approximately $388,000 clinical trial management fees payable to KMPL upon completion of the clinical trial have been reported as Accrued Expenses-related party, and approximately $387,000 of clinical trial CRO fees payable to Om Sai which has been reported as Accrued Expenses. The Company estimates that the total additional cost of the execution, regulatory submissions, and other activities for the Phase II clinical trial for Ebola will be approximately $872,000.